The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
BIIB Buyback image

Biogen Buyback

OLI recorded this information on 5/8/2015

Company: Biogen
Buyback: BIIB buyback
$Amount Authorized: $5,000,000,000
Buyback Details: Biogen (NASDAQ:BIIB) today announced that its Board of Directors has authorized a program to repurchase up to $5 billion of the Company's common stock. The share repurchase program does not have an expiration date. Biogen currently expects that purchases will be executed within a period of up to five years. The repurchased shares will be retired.

Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co. has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Co. also commercialize biosimilars of biologics and focuses on improving its pipeline in neuroscience and immunology. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis.

Biogen SEC Filing Email Alerts Service

Open the BIIB Page at The Online Investor »

BIIB — Key Stats (updated 3 hours, 41 minutes ago)
Company Name:  Biogen Inc
Stock buyback:  BIIB buyback
Website:  www.biogen.com
Sector:  Biotechnology
Number of ETFs Holding BIIB:  110
Total Market Value Held by ETFs:  $5.13B
Total Market Capitalization:  $28.37B
% of Market Cap. Held by ETFs:  18.09%
 

Open the BIIB Page at The Online Investor (in a new window) »
April 18, 2024  •  2:14 PM Eastern
BIIB — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree BIIB Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Buy (3.30 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
BIIB Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

BIIB Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.